Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 1, 2008, Pages 21-25

  Bantis, Athanasios ^a   Zissimopoulos, Athanasios ^a   Kalaitzis, Christos ^a   Giannakopoulos, Stilianos ^a   Sountoulides, Petros ^a   Parmenopoulou, Vanesa ^a   Agelonidou, Eleni ^a   Touloupidis, Stavros ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Bone scintigraphy; Gleason score; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN DERIVATIVE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GAMMA SCINTIGRAPHY; GLEASON SCORE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROSTATE CANCER; RADIOIMMUNOASSAY; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; WHOLE BODY SCINTISCANNING;

AGED; ANDROGEN ANTAGONISTS; DIAGNOSTIC IMAGING; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TREATMENT OUTCOME;

EID: 43249121398     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. Cancer J Clin 2006; 56: 106-130.
2. Eble JN. "Editorial." Mod Pathol 2004; 17: 1.
3. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240.
4. Catalona WJ, Smith DS, Ratliff Th et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1561.
5. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244.
6. Chodak GW. Maximum androgen blockade: a clinical update. Rev Urol 2005; 7 Suppl 5: S13-7
7. Wassersug RJ, Johnson TW. Modern-day eunuchs: motivations for and consequences of contemporary castration. Perspect Biol Med 2007; 50: 544-556.
8. Selli C, Milesi C. Neoadjuvant androgen deprivation before radical prostatectomy. A review. Minerva Urol Nefrol 2004; 56: 165-171.
9. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Canad. Med Assoc J 2007; 176: 1853-1858.
10. Terris MK, Klonecke AS, McDougall IR et al. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713-1717.
11. Spencer JA, Chng WJ, Hudson E et al. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Br J Radiol 1998; 71: 1130-1135.
12. Altay B, Kefi A, Nazli O et al. Comparison of Gleason scores from sextant prostate biopsies and radical prostatectomy specimens. Urol Int 2001; 67: 14-18.
13. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974. J Urol 2002; 167(2 Pt 2): 953-958 & 959.
14. Brawn PN. The differentiation of prostate carcinoma. Cancer 1983, 52: 246-251.
15. Epstein JI. Prostatic intraepithelial neoplasia. Adv Anat Pathol 1994, 1: 123-134.
16. Soloway MS, Ishikawa S, van der Zwaag R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology 1989; 33 (5 Suppl): 53-56.
17. Sim HG, Lau WK, Cheng CW. Predictors of androgen independence in metastatic prostate cancer. BJU Int 2004; 93: 1221-1224.
18. Ortega A, Alonso JC, Suarez M et al. Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels. Rev Esp Med Nucl 2000; 19: 409-415.
19. Wolff JM, Zimny M, Borchers H et al. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 376-381.
20. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712.
21. Hanif M, Zaidi P, Kamal S et al. Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. J Pak Med Assoc 2007; 57: 248-251.
22. Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-1083.
23. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989; 141: 1088-1090.
24. Rhoden EL, Torres O, Ramos GZ et al. Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy. Int Braz J Urol 2003; 29: 121-125 & 126.
25. Letaief B, Boughattas S, Hassine H, Essabbah H. Bone scan and prostate cancer. Ann Urol (Paris) 2000; 34: 254-265.
26. Ishikawa S, Soloway MS, van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139-1142.
27. Gleason DF. Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of prostate carcinoma. The prostate. Philadelphia, Lea & Febiger, 1977; pp 171-197.
28. Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 607-611.
29. Scher HI. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007; 13: 1488-1492.